Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs

D. Caccamo, L. R. Pisani, P. Mazzocchetti, R. Ientile, P. Calabresi, F. Pisani, C. Costa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Neuroprotection is conceived as one of the potential tool to prevent or slow neuronal death and hence a therapeutic hope to treat neurodegenerative diseases, like Parkinson’s and Alzheimer’s diseases. Increase of oxidative stress, mitochondrial dysfunction, excitotoxicity, inflammatory changes, iron accumulation, and protein aggregation have been identified as main causes of neuronal death and adopted as targets to test experimentally the putative neuroprotective effects of various classes of drugs. Among these agents, antiepileptic drugs (AEDs), both the old and the newer generations, have shown to exert protective effects in different experimental models. Their mechanism of action is mediated mainly by modulating the activity of sodium, calcium and potassium channels as well as the glutamatergic and GABAergic (gamma-aminobutyric acid) synapses. Neurological pathologies in which a neuroprotective action of AEDs has been demonstrated in specific experimental models include: cerebral ischemia, Parkinson’s disease, and Alzheimer’s disease. Although the whole of experimental data indicating that neuroprotection can be achieved is remarkable and encouraging, no firm data have been produced in humans so far and, at the present time, neuroprotection still remains a challenge for the future.

Original languageEnglish
Pages (from-to)1-13
Number of pages13
JournalNeurochemical Research
DOIs
Publication statusAccepted/In press - Dec 31 2015

Fingerprint

Neurodegenerative diseases
Neurodegenerative Diseases
Anticonvulsants
Parkinson Disease
Alzheimer Disease
Theoretical Models
Oxidative stress
Sodium Channels
Potassium Channels
Neuroprotective Agents
Pathology
Calcium Channels
Brain Ischemia
Synapses
gamma-Aminobutyric Acid
Cause of Death
Oxidative Stress
Therapeutics
Agglomeration
Iron

Keywords

  • AEDs
  • Experimental animal models
  • Neuroprotection

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Biochemistry

Cite this

Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases : Focus on Antiepileptic Drugs. / Caccamo, D.; Pisani, L. R.; Mazzocchetti, P.; Ientile, R.; Calabresi, P.; Pisani, F.; Costa, C.

In: Neurochemical Research, 31.12.2015, p. 1-13.

Research output: Contribution to journalArticle

Caccamo, D. ; Pisani, L. R. ; Mazzocchetti, P. ; Ientile, R. ; Calabresi, P. ; Pisani, F. ; Costa, C. / Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases : Focus on Antiepileptic Drugs. In: Neurochemical Research. 2015 ; pp. 1-13.
@article{e3fda041f76b42b9930b9ebb41379aa6,
title = "Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs",
abstract = "Neuroprotection is conceived as one of the potential tool to prevent or slow neuronal death and hence a therapeutic hope to treat neurodegenerative diseases, like Parkinson’s and Alzheimer’s diseases. Increase of oxidative stress, mitochondrial dysfunction, excitotoxicity, inflammatory changes, iron accumulation, and protein aggregation have been identified as main causes of neuronal death and adopted as targets to test experimentally the putative neuroprotective effects of various classes of drugs. Among these agents, antiepileptic drugs (AEDs), both the old and the newer generations, have shown to exert protective effects in different experimental models. Their mechanism of action is mediated mainly by modulating the activity of sodium, calcium and potassium channels as well as the glutamatergic and GABAergic (gamma-aminobutyric acid) synapses. Neurological pathologies in which a neuroprotective action of AEDs has been demonstrated in specific experimental models include: cerebral ischemia, Parkinson’s disease, and Alzheimer’s disease. Although the whole of experimental data indicating that neuroprotection can be achieved is remarkable and encouraging, no firm data have been produced in humans so far and, at the present time, neuroprotection still remains a challenge for the future.",
keywords = "AEDs, Experimental animal models, Neuroprotection",
author = "D. Caccamo and Pisani, {L. R.} and P. Mazzocchetti and R. Ientile and P. Calabresi and F. Pisani and C. Costa",
year = "2015",
month = "12",
day = "31",
doi = "10.1007/s11064-015-1809-5",
language = "English",
pages = "1--13",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",

}

TY - JOUR

T1 - Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases

T2 - Focus on Antiepileptic Drugs

AU - Caccamo, D.

AU - Pisani, L. R.

AU - Mazzocchetti, P.

AU - Ientile, R.

AU - Calabresi, P.

AU - Pisani, F.

AU - Costa, C.

PY - 2015/12/31

Y1 - 2015/12/31

N2 - Neuroprotection is conceived as one of the potential tool to prevent or slow neuronal death and hence a therapeutic hope to treat neurodegenerative diseases, like Parkinson’s and Alzheimer’s diseases. Increase of oxidative stress, mitochondrial dysfunction, excitotoxicity, inflammatory changes, iron accumulation, and protein aggregation have been identified as main causes of neuronal death and adopted as targets to test experimentally the putative neuroprotective effects of various classes of drugs. Among these agents, antiepileptic drugs (AEDs), both the old and the newer generations, have shown to exert protective effects in different experimental models. Their mechanism of action is mediated mainly by modulating the activity of sodium, calcium and potassium channels as well as the glutamatergic and GABAergic (gamma-aminobutyric acid) synapses. Neurological pathologies in which a neuroprotective action of AEDs has been demonstrated in specific experimental models include: cerebral ischemia, Parkinson’s disease, and Alzheimer’s disease. Although the whole of experimental data indicating that neuroprotection can be achieved is remarkable and encouraging, no firm data have been produced in humans so far and, at the present time, neuroprotection still remains a challenge for the future.

AB - Neuroprotection is conceived as one of the potential tool to prevent or slow neuronal death and hence a therapeutic hope to treat neurodegenerative diseases, like Parkinson’s and Alzheimer’s diseases. Increase of oxidative stress, mitochondrial dysfunction, excitotoxicity, inflammatory changes, iron accumulation, and protein aggregation have been identified as main causes of neuronal death and adopted as targets to test experimentally the putative neuroprotective effects of various classes of drugs. Among these agents, antiepileptic drugs (AEDs), both the old and the newer generations, have shown to exert protective effects in different experimental models. Their mechanism of action is mediated mainly by modulating the activity of sodium, calcium and potassium channels as well as the glutamatergic and GABAergic (gamma-aminobutyric acid) synapses. Neurological pathologies in which a neuroprotective action of AEDs has been demonstrated in specific experimental models include: cerebral ischemia, Parkinson’s disease, and Alzheimer’s disease. Although the whole of experimental data indicating that neuroprotection can be achieved is remarkable and encouraging, no firm data have been produced in humans so far and, at the present time, neuroprotection still remains a challenge for the future.

KW - AEDs

KW - Experimental animal models

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=84952643079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952643079&partnerID=8YFLogxK

U2 - 10.1007/s11064-015-1809-5

DO - 10.1007/s11064-015-1809-5

M3 - Article

AN - SCOPUS:84952643079

SP - 1

EP - 13

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

ER -